FDA grants EUA for Pfizer-BioNTech’s Covid-19 booster in children
The expanded EUA for use of booster dose in children is based on the findings from a Phase II/III clinical…

The expanded EUA for use of booster dose in children is based on the findings from a Phase II/III clinical…
The data was inadequate to conclude that the drug was effective in preventing disease progression, FDA noted.
The EC can terminate the agreement if the vaccine does not obtain marketing authorisation from EMA by the end of…
The vaccine doses planned to be supplied between June and August will now be delivered from September to Q4 of…
For the fiscal year, the operating cash flow witnessed a 11.1% rise to $8.63bn (JPY1,123.1bn).
The grant will support two trials of ebselen in 120 adult subjects with moderate or severe Covid-19.
The approval is based on findings from two Phase III clinical trials, ACTT-2 and COV-BARRIER.
This alliance is the third academic-industry partnership of API this year to develop therapies against viral variants.